Evercore Turns Neutral on Clorox as Shorts Unwind After Earnings

Why this matters: Evercore ISI upgraded CLX to In-Line this morning, breaking a run of downgrades from rival banks that had pushed the stock's short interest to its October highs. The upgrade lands the same day that retail attention hit 3.3 standard deviations above its 90-day average, and after shorts cut 17% of their position in a single week.

Analyst Reversal Cuts Against the Crowd

The Evercore move stands out precisely because it runs counter to recent Street direction. Five banks lowered their price targets on Clorox between October 5 and October 19. JP Morgan cut its target from $95 to $83. Barclays went from $84 to $80. Morgan Stanley moved from $97 to $87.

Evercore analyst Javier Escalante held his $99 target and lifted the rating from Underperform to In-Line. The stock sat at $88 when the change was reported. That $99 target is the highest on record in the recent analyst activity shown here, and the upgrade is the only rating improvement in that window.

The consensus mean target, last updated October 19, stands at $96.35, around 9% above Friday's close. JP Morgan and Barclays both carry Underweight ratings with targets below the current price, so the Street remains split.

Short Sellers Retreat After the Print

Two ORTEX articles published in the days before Clorox's October 30 earnings documented an aggressive short build: positions climbed roughly 30% over October to a peak near 12.5 million shares, or just above 10% of the free float. The thesis going into that print was clearly bearish.

It did not survive contact with results. Short interest now stands at 8.5% of the free float, down 17% on the week to around 10.3 million shares. That is a reversal of most of the pre-earnings accumulation, though the one-month figure remains positive at 15%, reflecting how far shorts pushed in early-to-mid October.

Among Clorox's closest peers, the short-interest unwinding is more pronounced than typical. This week's move is 2.1 standard deviations below the company's own historical weekly change rate, meaning the speed of the covering is unusual for CLX specifically, not just large in absolute terms.

Availability in the lending market sits at 352%, meaning roughly 3.5 shares are available to borrow for every one already lent out. That is the loosest the borrow market has been since the pre-October period. Cost to borrow is 0.54%, barely changed in six weeks. Short sellers face no friction in either direction.

Attention Spike Adds a Third Signal

Wikipedia page-view data tracked by ORTEX shows retail attention for Clorox hit a z-score of 3.3 relative to its own 90-day history, as of October 30. The Wikimedia Foundation data covers daily English-language article views. A reading at that level reflects unusually elevated interest for a household-products company.

This dataset has not been shown to lead Clorox's reported financial figures, so it speaks to attention, not to the underlying business. Still, a spike of that magnitude arriving on the same day as the earnings print and the short-interest reversal adds colour to how much scrutiny the stock attracted last week.

The ORTEX short score has fallen from a peak of 64.6 on October 28 to 54.2 on October 30, moving away from the more elevated readings that accompanied the pre-earnings short build.

Data summary

• SI % FF: 8.5%, down 17% on the week, up 15% on the month
• Evercore ISI: upgraded to In-Line from Underperform, $99 target maintained
• JP Morgan and Barclays: both Underweight with targets below current price
• Availability: 352%, the lending market is wide open
• Cost to borrow: 0.54%, flat for six weeks
• ORTEX short score: 54.2, down from 64.6 on October 28
• Retail attention z-score: 3.3 vs 90-day average, as of October 30 (Wikimedia Foundation data, attention signal only)